Clinical trial · Interventional
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve the efficacy? This study aims to explore the efficacy and safety of simultaneous integrated boost hyperfractionation radiotherapy combined with probiotics and Adalberg monoclonal antibody consolidation therapy for small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Limited Stage Small Cell Lung Cancer | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| concurrent Hyperfractionated Radiotherapy | Radiation | — | UNRESOLVED |
| Immunotherapy | Drug | Immunotherapy | ALIAS |
| Probiotics | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Probiotics Combined with Concurrent Hyperfractionated Radiotherapy and Adebrelimab Immunomaintenance
- description
- Chest radiotherapy (PTV-G: 54Gy/30F, bid; PTV-C: 45Gy/30F, bid) started before the fourth etoposide and cisplatin chemotherapy, and the subjects will be given probiotics before radiotherapy. Adebrelimab (1200mg) was given in the first week after radiotherapy, and mantained every 3 weeks for 2 year.
- interventionNames
- Drug: Probiotics
- Radiation: concurrent Hyperfractionated Radiotherapy
- Drug: Immunotherapy
- type
- PLACEBO_COMPARATOR
- label
- Concurrent Hyperfractionated Radiotherapy and Adebrelimab Immunomaintenance
- description
- Chest radiotherapy (PTV-G: 54Gy/30F, bid; PTV-C: 45Gy/30F, bid) started before the fourth etoposide and cisplatin chemotherapy. Adebrelimab (1200mg) was given in the first week after radiotherapy, and mantained every 3 weeks for 2 year.
- interventionNames
- Radiation: concurrent Hyperfractionated Radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Sign written informed consent before implementing any experimental procedures; 2. Age range: 18-80 years old; 3. Pathological diagnosis of small cell lung cancer; 4. Limited stage; 5. ECOG PS 0-1； 6. Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy; 7. Expected survival time\>3 months; Exclusion Criteria: 1. Progress after 2 induction treatments; 2. Severe emphysema, interstitial changes in the lungs, COPD patients; 3. Resting blood oxygen\<93; 4. Have a history of other malignant tumors and have received chemotherapy in the past 3 years; 5. History of chest radiotherapy;
References
Publications (0)
Data not yet available